✦ LIBER ✦

Long term assessment of patterns of treatment failure and survival in patients with stage I or II follicular lymphoma

✍ Scribed by Pelayo C. Besa; Peter W. McLaughlin; James D. Cox; Lillian M. Fuller

Publisher: John Wiley and Sons
Year: 1995
Tongue: English
Weight: 593 KB
Volume: 75
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19950501)75:9<2361::aid-cncr2820750928>3.0.co;2-n

No coin nor oath required. For personal study only.

✦ Synopsis

Background. Follicular lymphoma is a clearly defined type of malignant lymphoma. The many treatment approaches reported in the literature attest to the lack of agreement on its best management. The treatment experiences of patients with Stage I or I1 follicular lymphoma who were at risk for at least 5 years were reviewed to assess their survival, disease free survival, and patterns of failure.

Methods. Between 1974 and 1988, 144 patients with Stage I or I1 follicular lymphoma were treated at The University of Texas M. D. Anderson Cancer Center. Initial staging studies included lymphangiography in 87% of the patients, computerized tomography of the abdomen and pelvis in SO%, bone marrow biopsy in 98%, and diagnostic or staging laparotomy in 33%. Forty-five patients were treated with regional radiotherapy, 84 patients with combined chemotherapy and radiotherapy, and 15 patients were treated with chemotherapy alone.

Results. With a median follow-up of 8.7 years (range, 48-182 months) the actuarial survival rates at 5,10, and 15 years were 81,69, and 63%, respectively. The freedom from relapse (FFR) rates were 66, 56, and 46%, respectively. The FFR rate was better for patients treated with chemotherapy-radiotherapy than for patients treated with radiotherapy alone (63 vs. 35% at 15 years). In addition, there were no relapses after 7.5 years in patients treated with chemotherapy-radiotherapy, but relapses continued even beyond 15 years in patients treated with radiotherapy alone. Univariate analysis for each of the

📜 SIMILAR VOLUMES

Treatment outcome and pattern of failure

Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma

✍ Chi-Cheng Li; Hwei-Fang Tien; Jih-Luh Tang; Ming Yao; Yao-Chang Chen; Ih-Jen Su; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 1 views

## Abstract ## BACKGROUND Sinonasal natural killer (NK)/T‐cell or T‐cell lymphoma behaves quite differently from other lymphomas. The objective of this study was to investigate clinical features, treatment outcomes, and failure patterns in patients with this type of sinonasal lymphoma. ## METHODS

Treatment, patterns of failure, and surv

Treatment, patterns of failure, and survival of patients with Stage I nodal and extranodal non-Hodgkin's lymphomas, according to data in the population-based registry of the comprehensive cancer centre west

✍ Augustinus D. Krol; Jo Hermans; Lilian Dawson; Simone Snijder; Pierre W. Wijerma 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 2 views

## BACKGROUND. Primary extranodal lymphomas (EN-NHLs) are a heterogeneous category of tumors that are considered to be different from primary nodal non-Hodgkin's lymphomas (N-NHLs). To what extent these differences have clinical implications is currently not very clear, because knowledge of EN-NHL

Long-term survival in thyroid carcinoma.

Long-term survival in thyroid carcinoma. Patients with follicular the Oslo experience: Variations with encapsulation, growth pattern, time of diagnosis, sex, age, and previous thyroid surgery

✍ Johan Høie; Anna E. Stenwig 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 435 KB 👁 1 views

In 98 follicular thyroid carcinoma patients with a follow-up of 10-32 years, 1 O-year survival varied in subgroups from 15.5-63.4%. Survival with encapsulated primary tumors was 46.7%, compared to 26.9% in widely invasive tumors, and varied from 59.9-35.8% with growth pattern. In patients younger th

S-phase fraction as an independent progn

S-phase fraction as an independent prognostic factor of long-term overall survival in patients with early-stage or locally advanced invasive breast carcinoma

✍ Vielh, Philippe ;Carton, Mathieu ;Padoy, Eliane ;de Rycke, Yann ;Klijanienko, Je 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB 👁 2 views

Long-term results of the treatment of pa

Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group

✍ David J. Inwards; Paul A. S. Fishkin; David W. Hillman; David W. Brown; Stephen 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 1 views

## Abstract ## BACKGROUND. The objective of this study was to test cladribine (2‐CDA) alone and in combination with rituximab in patients with mantle cell lymphoma (MCL). ## METHODS. Patients with MCL were treated on 2 sequential trials. In Trial 95‐80‐53, patients received 2‐CDA as initial ther